RAPT RAPT Therapeutics
- 8.280
- -0.050-0.60%
- 8.390
- +0.110+1.33%
RAPT Therapeutics News
Daily rights tracking | Google's bullish ratio soared to 70%! Earn 2x option bonuses with multiple calls in a single transaction
Nvidia rose more than 6% last Friday and surged 15% throughout the week. 2.7 million options were sold, and multiple calls due this Friday earned 3 times the premium.
Daily rights tracking | Market capitalization soared to $55.6 billion overnight! Tesla's bullish sentiment is picking up
Nvidia fell more than 3% overnight, and some large investors bought two large bearish orders in a row when the stock price was 794.2 US dollars, involving nearly 50 million US dollars.
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Hold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertainties
Maintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertainty
HC Wainwright & Co. : Reiterates RAPT Therapeutics (RAPT.US) neutral rating.
HC Wainwright & Co. : Reiterates RAPT Therapeutics (RAPT.US) neutral rating.
HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
RAPT Therapeutics Announces Promising Results From Phase 2 Trial of Tivumecirnon in Combination With Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status- Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease- Confirmed ORR of 22.2% in subset
JP Morgan Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $13
JP Morgan analyst Anupam Rama maintains RAPT Therapeutics with a Neutral and lowers the price target from $15 to $13.
RAPT Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 55.5% JP Morgan $15 → $13 Maintains Neutral 02/22/2024 19.62% UBS $61 → $10 Downgrades Buy → Ne
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns
Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)
RAPT Therapeutics GAAP EPS of -$0.80
RAPT Therapeutics Q4 EPS $(0.80) Beats $(0.86) Estimate, Cash Balance of $158.9M as of December 31, 2023
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.86) by 6.98 percent. This is a 25 percent decrease over losses of $(0.64
Press Release: RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
RAPT Therapeutics, Inc. (Nasdaq: RAPT) today reported financial results for the fourth quarter and year ended December 31, 2023.
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancerSOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutic
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$RAPT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. ("RAPT" or
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
RAPT Therapeutics Clinical Trials Halted by FDA
Analysis
Price Target
No Data
